{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:42:35Z","timestamp":1760186555552,"version":"build-2065373602"},"reference-count":123,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.hoc.2014.08.005","type":"journal-article","created":{"date-parts":[[2014,9,26]],"date-time":"2014-09-26T18:51:17Z","timestamp":1411757477000},"page":"1055-1071","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Transplantation in Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"28","author":[{"given":"Fabienne","family":"McClanahan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Gribben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2014.08.005_bib1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Chiorazzi","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2014.08.005_bib2","first-page":"9","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"year":"2012","series-title":"SEER cancer statistics review, 1975-2009 (vintage 2009 populations)","key":"10.1016\/j.hoc.2014.08.005_bib3"},{"key":"10.1016\/j.hoc.2014.08.005_bib4","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib5","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2014.08.005_bib6","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2014.08.005_bib7","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 mutation and survival in chronic lymphocytic leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib8","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/leu.2013.190","article-title":"Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab","volume":"27","author":"Fink","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.005_bib9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/asheducation-2013.1.158","article-title":"Treatment of older patients with chronic lymphocytic leukemia: key questions and current answers","volume":"2013","author":"Shanafelt","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.hoc.2014.08.005_bib10","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1200\/JCO.2013.49.6547","article-title":"Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: final analysis of an open-label phase II study","volume":"32","author":"Hillmen","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib11","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ajh.23668","article-title":"Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients","volume":"89","author":"Fo\u00e0","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2014.08.005_bib12","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2014.08.005_bib13","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1200\/JCO.2009.25.3187","article-title":"Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia","volume":"28","author":"Wierda","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib14","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1182\/blood-2010-12-323980","article-title":"Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia","volume":"117","author":"Wierda","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib15","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2011-04-348656","article-title":"Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study","volume":"118","author":"Wierda","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2014.08.005_bib17","first-page":"7009","article-title":"A\u00a0phase 1b\/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and related diseases","volume":"32","author":"Jaglowski","year":"2014","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1016\/j.hoc.2014.08.005_bib18","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.hoc.2014.08.005_bib19","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","article-title":"Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study","volume":"15","author":"Burger","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib20","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","article-title":"Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Brown","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib21","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2014.08.005_bib22","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase i study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib23","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2014.08.005_bib24","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/asheducation-2013.1.151","article-title":"Immunotherapeutic strategies including transplantation: eradication of disease","volume":"2013","author":"Gribben","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.hoc.2014.08.005_bib25","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","article-title":"Graft-versus-leukemia effects of transplantation and donor lymphocytes","volume":"112","author":"Kolb","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/320084a0","article-title":"Localization of gene for human p53 tumour antigen to band 17p13","volume":"320","author":"Isobe","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2014.08.005_bib27","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2008-04-154070","article-title":"Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up","volume":"112","author":"Zenz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/leu.2008.274","article-title":"The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype","volume":"23","author":"Dicker","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.005_bib29","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2009-03-210591","article-title":"De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience","volume":"114","author":"Tam","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib30","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO.2011.39.2688","article-title":"Bendamustine in combination with rituximab\u00a0for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II Trial of the German Chronic Lymphocytic Leukemia Study Group","volume":"30","author":"Fischer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib31","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1200\/JCO.2010.31.1811","article-title":"Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712","volume":"29","author":"Woyach","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib32","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib33","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23824","article-title":"Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab","volume":"113","author":"Zent","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2014.08.005_bib34","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1200\/JCO.2011.35.9695","article-title":"Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial","volume":"30","author":"Pettitt","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib35","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2011-01-329177","article-title":"Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia","volume":"118","author":"Parikh","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib36","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1200\/JCO.2008.21.1128","article-title":"Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group","volume":"27","author":"Stilgenbauer","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib37","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.23737","article-title":"Chemoimmunotherapy for relapsed\/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells","volume":"89","author":"Zent","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2014.08.005_bib38","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1080\/10428190701724801","article-title":"Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features","volume":"48","author":"Bowen","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2014.08.005_bib39","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1182\/blood-2011-03-341032","article-title":"Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib40","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood-2010-08-304683","article-title":"Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL","volume":"117","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib41","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood.V99.10.3554","article-title":"Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study","volume":"99","author":"Keating","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib42","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.2007.11.8513","article-title":"Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"26","author":"Tsimberidou","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib43","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3324\/haematol.2013.086207","article-title":"A\u00a0phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"98","author":"Brown","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2014.08.005_bib44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/sj.leu.2404441","article-title":"Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus","volume":"21","author":"Dreger","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.005_bib45","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib46","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1182\/blood-2011-11-312421","article-title":"Risk categories and refractory CLL in the era of chemoimmunotherapy","volume":"119","author":"Zenz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib47","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood.V82.4.1366.1366","article-title":"Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia","volume":"82","author":"Rabinowe","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib48","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1200\/JCO.1994.12.4.748","article-title":"Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results","volume":"12","author":"Khouri","year":"1994","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib49","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.1998.16.8.2817","article-title":"Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies","volume":"16","author":"Khouri","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib50","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib51","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib52","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/bmt.2014.55","article-title":"Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation","volume":"49","author":"Passweg","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.005_bib53","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","article-title":"Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial","volume":"116","author":"Dreger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib54","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2007.15.4757","article-title":"Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"26","author":"Sorror","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib55","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1200\/JCO.2008.16.2982","article-title":"Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia with 17p- deletion: a retrospective EBMT analysis","volume":"26","author":"Schetelig","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib56","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1002\/cncr.26091","article-title":"Nonmyeloablative allogeneic stem cell transplantation in relapsed\/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome","volume":"117","author":"Khouri","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2014.08.005_bib57","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/leu.2012.228","article-title":"Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome","volume":"27","author":"Brown","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.005_bib58","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1200\/JCO.2005.04.531","article-title":"Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia","volume":"23","author":"Moreno","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib59","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.leu.2402905","article-title":"Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning","volume":"17","author":"Dreger","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.005_bib60","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2005-05-1778","article-title":"Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia","volume":"106","author":"Gribben","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib61","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1200\/JCO.2003.12.011","article-title":"Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group","volume":"21","author":"Schetelig","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib62","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/blood-2012-11-469627","article-title":"TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial","volume":"121","author":"Dreger","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib63","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"Wang","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2014.08.005_bib64","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Quesada","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.hoc.2014.08.005_bib65","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib66","article-title":"Recurrent mutations refine prognosis in chronic lymphocytic leukemia","author":"Baliakas","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.005_bib67","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.exphem.2012.10.008","article-title":"Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study","volume":"41","author":"Michallet","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.hoc.2014.08.005_bib68","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/leu.2010.165","article-title":"The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry","volume":"24","author":"Michallet","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.005_bib69","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clml.2013.03.012","article-title":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or Richter syndrome","volume":"13","author":"Tsimberidou","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.hoc.2014.08.005_bib70","first-page":"920","article-title":"Subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allo-SCT In CLL with 17p- or refractory to fludarabine - interim analysis of the CLL2O trial of the GCLLSG and FCGCLL\/MW","volume":"116","author":"Stilgenbauer","year":"2010","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.hoc.2014.08.005_bib71","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00277-012-1579-y","article-title":"Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia","volume":"92","author":"Krejci","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.hoc.2014.08.005_bib72","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1002\/cncr.24531","article-title":"Risk score for outcome after allogeneic hematopoietic stem cell transplantation","volume":"115","author":"Gratwohl","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2014.08.005_bib73","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.blre.2011.01.001","article-title":"Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies","volume":"25","author":"Boettcher","year":"2011","journal-title":"Blood Rev"},{"key":"10.1016\/j.hoc.2014.08.005_bib74","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.2005.04.021","article-title":"Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival","volume":"23","author":"Moreton","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib75","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","article-title":"Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial","volume":"30","author":"Boettcher","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib76","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3324\/haematol.2013.099796","article-title":"The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy","volume":"99","author":"Santacruz","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2014.08.005_bib77","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1182\/blood-2013-11-538116","article-title":"Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL","volume":"123","author":"Strati","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib78","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3324\/haematol.2008.000273","article-title":"Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation","volume":"94","author":"Farina","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2014.08.005_bib79","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/leu.2013.52","article-title":"Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia","volume":"27","author":"Logan","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.005_bib80","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/bjh.12197","article-title":"Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia","volume":"160","author":"Richardson","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2014.08.005_bib81","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3109\/10428194.2012.666661","article-title":"Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?","volume":"53","author":"Machaczka","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2014.08.005_bib82","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/sj.bmt.1705130","article-title":"Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease","volume":"36","author":"Toze","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.005_bib83","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.hoc.2013.01.007","article-title":"The evolving role of stem cell transplantation in chronic lymphocytic leukemia","volume":"27","author":"Dreger","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.hoc.2014.08.005_bib84","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib85","first-page":"2880","article-title":"Outcome of chronic lymphocytic leukemia (CLL) patients that failed allogeneic stem cell transplantation","volume":"122","author":"Benjamini","year":"2013","journal-title":"Blood ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.hoc.2014.08.005_bib86","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2010-09-308775","article-title":"Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation","volume":"117","author":"Michallet","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib87","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/blood-2010-11-317073","article-title":"Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC","volume":"117","author":"Sutton","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib88","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/bmt.2011.117","article-title":"Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial","volume":"47","author":"Brion","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2014.08.005_bib89","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1182\/blood-2011-09-378505","article-title":"Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial","volume":"119","author":"Dreger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib90","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2006.05982.x","article-title":"High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia","volume":"133","author":"Milligan","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2014.08.005_bib91","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1182\/blood-2013-05-498287","article-title":"Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies","volume":"122","author":"Hallek","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib92","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2013-09-453092","article-title":"How will B-cell-receptor-targeted therapies change future CLL therapy?","volume":"123","author":"Jones","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib93","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12185-013-1479-5","article-title":"Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies","volume":"99","author":"Davila","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.hoc.2014.08.005_bib94","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.hoc.2014.08.005_bib95","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1182\/blood-2012-12-470005","article-title":"Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)","volume":"121","author":"Shanafelt","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib96","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib97","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1182\/blood-2012-08-448332","article-title":"Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide","volume":"121","author":"Ramsay","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib98","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3324\/haematol.2009.005835","article-title":"Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia","volume":"94","author":"Aue","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2014.08.005_bib99","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2009-09-242438","article-title":"Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway","volume":"115","author":"Lapalombella","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib100","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study","volume":"24","author":"Chanan-Khan","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib101","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","article-title":"Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma","volume":"27","author":"Witzig","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib102","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.2012.42.8623","article-title":"Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia","volume":"31","author":"Badoux","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib103","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.2007.13.9709","article-title":"Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia","volume":"26","author":"Andritsos","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib104","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"Ferrajoli","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib105","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2010.29.8133","article-title":"Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia","volume":"29","author":"Chen","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2014.08.005_bib106","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2011-03-339077","article-title":"Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia","volume":"118","author":"Badoux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib107","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1182\/blood-2013-04-495341","article-title":"Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia","volume":"122","author":"Strati","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib108","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in\u00a0vitro and in\u00a0vivo","volume":"119","author":"Ponader","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib109","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib110","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","article-title":"The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia","volume":"119","author":"de Rooij","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib111","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib112","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1182\/blood-2010-11-315705","article-title":"The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib113","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.leukres.2013.06.006","article-title":"Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia","volume":"37","author":"Stephens","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.hoc.2014.08.005_bib114","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1038\/leu.2011.375","article-title":"Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features","volume":"26","author":"Woyach","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2014.08.005_bib115","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nri2635","article-title":"Engineering lymphocyte subsets: tools, trials and tribulations","volume":"9","author":"June","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.hoc.2014.08.005_bib116","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2014.08.005_bib117","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib118","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib119","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T\u00a0cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.hoc.2014.08.005_bib120","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2014.08.005_bib121","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2014.08.005_bib122","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.canlet.2013.10.004","article-title":"Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells","volume":"343","author":"Xu","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.hoc.2014.08.005_bib123","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdt511","article-title":"The impact of allogeneic stem cell transplantation on the natural course of poor-risk chronic lymphocytic leukemia as defined by the EBMT consensus criteria: a retrospective donor versus no donor comparison","volume":"25","author":"Herth","year":"2014","journal-title":"Ann Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858814001051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858814001051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:01:23Z","timestamp":1760184083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858814001051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":123,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0889858814001051"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2014.08.005","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transplantation in Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2014.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}